VIRGINIA RETIREMENT SYSTEMS ET Al Acquires 74,900 Shares of Illumina, Inc. $ILMN

VIRGINIA RETIREMENT SYSTEMS ET Al raised its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 27.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 348,011 shares of the life sciences company’s stock after purchasing an additional 74,900 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Illumina were worth $45,645,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. HighPoint Advisor Group LLC raised its position in shares of Illumina by 3.7% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock valued at $291,000 after acquiring an additional 80 shares during the last quarter. Chesapeake Capital Corp IL bought a new stake in shares of Illumina during the 4th quarter valued at $415,000. Crossmark Global Holdings Inc. raised its position in shares of Illumina by 52.3% during the 4th quarter. Crossmark Global Holdings Inc. now owns 12,461 shares of the life sciences company’s stock valued at $1,634,000 after acquiring an additional 4,278 shares during the last quarter. Ethic Inc. raised its position in shares of Illumina by 14.4% during the 4th quarter. Ethic Inc. now owns 16,910 shares of the life sciences company’s stock valued at $2,218,000 after acquiring an additional 2,127 shares during the last quarter. Finally, Ballentine Partners LLC raised its position in shares of Illumina by 5.1% during the 4th quarter. Ballentine Partners LLC now owns 11,817 shares of the life sciences company’s stock valued at $1,550,000 after acquiring an additional 573 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Insider Transactions at Illumina

In other news, SVP Patricia Leckman sold 2,370 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total value of $275,346.60. Following the sale, the senior vice president directly owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. This represents a 12.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Christensen Jakob Wedel sold 700 shares of the stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total transaction of $97,328.00. Following the completion of the transaction, the senior vice president directly owned 15,056 shares in the company, valued at approximately $2,093,386.24. This represents a 4.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.90% of the stock is currently owned by corporate insiders.

Illumina Trading Up 2.2%

Illumina stock opened at $145.70 on Wednesday. The firm has a 50-day moving average of $127.79 and a 200-day moving average of $128.81. Illumina, Inc. has a one year low of $77.50 and a one year high of $155.53. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The company has a market cap of $22.04 billion, a price-to-earnings ratio of 26.49, a P/E/G ratio of 2.36 and a beta of 1.42.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the prior year, the business posted $0.97 EPS. The company’s quarterly revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, equities analysts expect that Illumina, Inc. will post 5.2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on ILMN shares. JPMorgan Chase & Co. upped their target price on shares of Illumina from $120.00 to $125.00 and gave the company a “neutral” rating in a research report on Friday, May 1st. UBS Group reiterated a “neutral” rating and set a $135.00 target price on shares of Illumina in a research report on Friday, February 6th. Stifel Nicolaus upped their target price on shares of Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. Piper Sandler decreased their price target on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a report on Monday, February 9th. Finally, Guggenheim boosted their price target on shares of Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a report on Monday, January 26th. Six equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $131.06.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.